Oncology – Page 33

Chemoradiotherapy After Induction Chemotherapy: Enhancing R0 Resection Rates in Unresectable Pancreatic Cancer—Insights from the CONKO-007 Trial

By MedXY 09/10/2025

The CONKO-007 trial reveals that adding chemoradiotherapy after induction chemotherapy increases margin-negative (R0) resections in surgically treated unresectable pancreatic cancer but does not improve overall survival.

Clinical Updates news Oncology Specialties

Prognostic Role of HER2 Amplification and Mutations in Metastatic Colorectal Cancer: Insights from Eight Randomized Trials

By MedXY 09/10/2025

HER2 amplification/mutation in RAS/BRAF wild-type metastatic colorectal cancer is a negative prognostic factor but does not predict differential benefit from bevacizumab or anti-EGFR therapies, based on analysis of 1,604 patients across eight randomized trials.

news Oncology Specialties

Cell-Based Ciliary Neurotrophic Factor Therapy for Macular Telangiectasia Type 2: Clinical Advances and Therapeutic Implications

By MedXY 09/10/2025

Phase 3 trials demonstrate that encapsulated cell therapy NT-501 significantly slows photoreceptor loss in MacTel, marking a promising disease-modifying approach with an acceptable safety profile.

Medical News OB/GYN & Women's Health Oncology Specialties

Beyond Cervical Cancer: The Rising Threat of HPV-Linked Oropharyngeal Cancer in Men

By MedXY 09/09/2025

HPV-related oropharyngeal cancer incidence has surpassed cervical cancer, with men facing a 5-10 fold higher risk. Understanding this shift, symptoms, risks, and the critical role of HPV vaccination can transform prevention and early detection.

Clinical Updates news Oncology Specialties

KEYNOTE-585 vs MATTERHORN in Gastric Cancer: Insights from Divergent Trial Outcomes

By MedXY 09/09/2025

The KEYNOTE-585 trial adding pembrolizumab to perioperative chemotherapy did not significantly improve event-free survival in esophagogastric cancer, while the MATTERHORN trial showed durvalumab plus FLOT chemotherapy improves outcomes, establishing a new standard of care.

Clinical Updates OB/GYN & Women's Health Oncology Specialties

Breastfeeding After Hormone Receptor-Positive Breast Cancer: Insights From the POSITIVE Trial

By MedXY 09/09/2025

The POSITIVE trial reveals that two thirds of women with early hormone receptor-positive breast cancer successfully breastfed post-treatment, without a significant increase in cancer recurrence risk, offering reassurance to women considering pregnancy and breastfeeding after breast cancer.

OB/GYN & Women's Health Oncology Specialties

ADAGIO Trial Illuminates Adavosertib’s Potential in Recurrent Uterine Serous Carcinoma Amidst Safety Challenges

By MedXY 09/09/2025

The ADAGIO phase IIb study assessed adavosertib in recurrent uterine serous carcinoma post-platinum therapy, revealing modest efficacy and significant toxicity, with biomarker trends suggesting CCNE1/cyclin E1 as potential response predictors.

Clinical Updates news Oncology Specialties

Long-Term Real-World Outcomes of Adjuvant Anti-PD-1 Checkpoint Inhibition Versus Targeted Therapy in Stage III Melanoma: A Comprehensive Review

By MedXY 09/09/2025

This review synthesizes current evidence on long-term real-world efficacy of adjuvant anti-PD-1 immunotherapy and targeted BRAF/MEK inhibitor therapy in stage III melanoma, highlighting differential recurrence risks, survival benefits, and treatment duration implications.

Clinical Updates Oncology Specialties

Patritumab Deruxtecan: A Promising New Hope in Advanced Non-Small Cell Lung Cancer Post Platinum and Immunotherapy

By MedXY 09/08/2025

Patritumab deruxtecan (HER3-DXd) demonstrates notable efficacy and manageable safety in heavily pretreated advanced NSCLC, including patients without EGFR mutations, offering a potential new treatment avenue.

Clinical Updates news Oncology Specialties

Avutometinib Plus Defactinib: A Promising Treatment for Recurrent Low-Grade Serous Ovarian Cancer

By MedXY 09/08/2025

This phase II study demonstrates that the combination of avutometinib and defactinib offers significant clinical benefit with manageable safety in recurrent low-grade serous ovarian cancer, particularly in KRAS-mutant tumors.

Clinical Updates Oncology Specialties

Efficacy and Challenges of Pazopanib in Advanced Extrapancreatic Neuroendocrine Tumors: Insights from the Alliance A021202 Trial

By MedXY 09/08/2025

The randomized phase II Alliance A021202 trial demonstrated that pazopanib significantly improves progression-free survival in advanced extrapancreatic neuroendocrine tumors, confirming VEGF pathway as a therapeutic target but highlighting safety concerns that preclude further development.

Clinical Updates news Oncology Specialties

Xevinapant Fails to Improve Outcomes in Locally Advanced Head and Neck Cancer: Insights from the Phase III TrilynX Trial

By MedXY 09/08/2025

The TrilynX phase III study showed that adding xevinapant to platinum-based chemoradiotherapy did not improve event-free survival and was associated with worse overall survival and higher toxicity in unresected locally advanced squamous cell carcinoma of the head and neck.

Clinical Updates news Oncology Pathology & Lab Medicine

Revolutionizing Early Detection of Pancreatic Cancer: A cfDNA Fragmentomics and Machine Learning Model

By MedXY 09/08/2025

A new cell-free DNA fragmentomics model combined with machine learning achieves high accuracy for early pancreatic cancer detection, potentially improving patient outcomes through timely intervention.

Clinical Updates Oncology

Neoadjuvant Osimertinib in Resectable EGFR-Mutated NSCLC: Advancing Preoperative Therapeutics

By MedXY 09/08/2025

Neoadjuvant osimertinib, alone or with chemotherapy, significantly improves major pathological response rates in resectable EGFR-mutated NSCLC, offering a promising approach to enhance surgical outcomes and event-free survival with an acceptable safety profile.

Clinical Updates news Oncology Specialties

Bridging the Gap: Addressing Inconsistent Reporting of Venous and Arterial Thrombotic Events in Cancer Clinical Trials

By MedXY 09/08/2025

Venous and arterial thrombotic events in cancer patients are underreported in clinical trials, impairing risk assessment and prevention strategies. Uniform and comprehensive reporting is imperative to improve patient outcomes and guide therapeutic decisions.

Clinical Updates Diabetes & Endocrinology news Oncology

Type 2 Diabetes and Colorectal Cancer: Immune Landscape Shapes Risk and Survival Outcomes

By MedXY 09/08/2025

Type 2 diabetes increases colorectal cancer risk and worsens survival, particularly in tumors with low immune cell infiltration, highlighting the interplay between metabolic and immune factors in cancer progression and prognosis.

Clinical Updates news OB/GYN & Women's Health Oncology

EPIK-O Trial Explores Alpelisib plus Olaparib Versus Chemotherapy in Platinum-Resistant High-Grade Serous Ovarian Cancer Without BRCA Mutation

By MedXY 09/08/2025

The phase III EPIK-O trial showed no progression-free survival benefit of alpelisib plus olaparib over chemotherapy in BRCA wild-type platinum-resistant or refractory high-grade serous ovarian cancer, highlighting treatment challenges and biomarker insights.

Clinical Updates news Oncology

FDA Approval of Trastuzumab Deruxtecan: Advancing Treatment for HR-Positive HER2-Low and Ultralow Metastatic Breast Cancer

By MedXY 09/08/2025

Trastuzumab deruxtecan (T-DXd) gains FDA approval for HR-positive, HER2-low and HER2-ultralow unresectable or metastatic breast cancer after endocrine therapy progression, offering significant progression-free survival benefits over chemotherapy.

Family Medicine & Nutrition news Oncology

10 Habits That Cancer Cells Fear: Building Your Body’s Natural Defense

By MedXY 09/08/2025

Explore ten evidence-based lifestyle habits that significantly reduce cancer risk and empower your body’s natural defenses against cancer development.

Clinical Updates Oncology Specialties

Updated Phase III HARMONi Trial Data Reveal Enhanced Survival Benefits of Ivonescimab in NSCLC

By MedXY 09/07/2025

Recent updates from the global Phase III HARMONi study demonstrate envafolimab’s significant improvement in overall and progression-free survival in NSCLC, with consistent benefits across diverse populations, reinforcing its emerging role in lung cancer therapy.